Emerging Treatments for Patients With Relapsed/Refractory Follicular Lymphoma
Key Clinical Takeaways
-
Design/Population: At the 2025 Lymphoma, Leukemia & Myeloma (LL&M) Congress, Erin Mulvey, MD, Weill Cornell Medicine, reviewed ongoing and approved therapies for patients with relapsed/refractory follicular lymphoma (FL).
-
Key Outcomes: The tofacitinib + rituximab + lenalidomide regimen received FDA approval (2026) for relapsed/refractory FL with strong response rates. Cetuximabtine + rituximab (antibody–drug conjugate) showed promising efficacy in phase 2 expansion cohorts, and taimestat continues evaluation alone and in combinations. Bispecific antibodies (mosunetuzumab, epcoritamab) and CAR T-cell therapies demonstrated high overall and durable responses.
-
Clinical Relevance: Expanding immunotherapy and combination options are improving outcomes in high-risk FL (POD24, high tumor burden), supporting a more personalized and potentially curative treatment paradigm.
At the 2025 Lymphoma, Leukemia & Myeloma (LL&M) Congress in New York, New York, Erin Mulvey, MD, Weill Cornell Medicine, New York, New York, discusses emerging therapeutic options for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL) including monoclonal and bispecific antibodies, as well as CAR T-cell therapy, which have demonstrated promising efficacy and duration of responses among patients.
Source:
Mulvey E. Advances in R/R Follicular Lymphoma: Diagnostic Approaches and Novel Therapeutic Options. Presented at Lymphoma, Leukemia & Myeloma Congress; October 14-17, 2025. New York, NY.
